Migraine is a complex neurologic disorder, the origin of which cannot be ascribed to a single brain site or mechanism. It is a chronic condition with recurrent episodic attacks lasting 4-72 hours when not treated, characterized by headache and associated symptoms.

Key Migraine Facts: 

  • The prevalence of migraine is significant, with 35 million patients in US and 32.5 million patients in the EU
  • Migraine affects 6% of men and 18% of women - often hormonally related
  • There is a strong genetic component in 70% of migraine sufferers
  • Migraine attacks are characterized by headache, nausea/vomiting, photophobia/phonophobia, functional disability, visual disturbance
  • Approximately 50 to 60% of migraine patients in the US and EU suffer from high frequency episodic migraine (EM) and chronic migraine (CM)
  • Patients eligible for migraine prevention are under-treated today (only 10% to 30% use prophylactic therapy). There is significant dissatisfaction with current treatments, and large numbers are refractory or intolerant to existing treatment options.

Teva is working to bring relief to people suffering from migraines – and in particular the destruction of quality of life that chronic or high frequency episodic migraine brings. 

TEV-48125 is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). CGRP causes headaches in migraine patients, and we know that CGRP levels are elevated during migraine. As such, targeting CGRP has the potential to change the way migraine is treated. TEV-48125 is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.

TEV-48125 demonstrates our determination to develop much needed treatment options for people suffering from migraine. We continue to pursue effective solutions in the prevention and treatment of migraine in order to make a real and meaningful difference to patients’ lives.